Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Safety and Efficacy of NNC 0142-0000-0002 in Subjects With Moderately to Severely Active Crohn's Disease

ClinicalTrials.gov ID: NCT01203631

Public ClinicalTrials.gov record NCT01203631. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 26, 2026, 5:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomised, Double-blind, Parallel-group, Placebo Controlled Induction Trial to Assess the Clinical Efficacy and Safety of NNC 0142-0000-0002 in Subjects With Moderately to Severely Active Crohn's Disease

Study identification

NCT ID
NCT01203631
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Janssen Research & Development, LLC
Industry
Enrollment
78 participants

Conditions and interventions

Interventions

  • NNC 0142-0000-0002 Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 31, 2011
Primary completion
Apr 30, 2013
Completion
Apr 30, 2013
Last update posted
Jul 31, 2016

2011 – 2013

United States locations

U.S. sites
16
U.S. states
11
U.S. cities
16
Facility City State ZIP Site status
Novo Nordisk Clinical Trial Call Center Anaheim California 92801
Novo Nordisk Clinical Trial Call Center Lakewood Colorado 80215
Novo Nordisk Clinical Trial Call Center Chicago Illinois 60637
Novo Nordisk Clinical Trial Call Center Louisville Kentucky 40202
Novo Nordisk Clinical Trial Call Center Annapolis Maryland 21401
Novo Nordisk Clinical Trial Call Center Chevy Chase Maryland 20815
Novo Nordisk Clinical Trial Call Center Towson Maryland 21204
Novo Nordisk Clinical Trial Call Center Chesterfield Michigan 48047
Novo Nordisk Clinical Trial Call Center Troy Michigan 48098
Novo Nordisk Clinical Trial Call Center New York New York 10029
Novo Nordisk Clinical Trial Call Center Asheville North Carolina 28801-4109
Novo Nordisk Clinical Trial Call Center Fayetteville North Carolina 28304
Novo Nordisk Clinical Trial Call Center Raleigh North Carolina 27612
Novo Nordisk Clinical Trial Call Center Germantown Tennessee 38138-1741
Novo Nordisk Clinical Trial Call Center Charlottesville Virginia 22911
Novo Nordisk Clinical Trial Call Center Milwaukee Wisconsin 53215-5217

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01203631, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 31, 2016 · Synced Jun 26, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01203631 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →